NASDAQ:GLMD - Galmed Pharmaceuticals Stock Price, Price Target & More

Galmed Pharmaceuticals trades on the NASDAQ under the ticker symbol "GLMD."

Galmed Pharmaceuticals (NASDAQ:GLMD) issued its quarterly earnings data on Wednesday, May, 16th. The biopharmaceutical company reported ($0.17) earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of ($0.23) by $0.06. The biopharmaceutical company earned $0.27 million during the quarter, compared to the consensus estimate of $0.29 million. Galmed Pharmaceuticals had a negative return on equity of 110.46% and a negative net margin of 1,073.09%. View Galmed Pharmaceuticals' Earnings History.

Galmed Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Monday, July, 30th 2018. View Earnings Estimates for Galmed Pharmaceuticals.

4 brokers have issued 1-year target prices for Galmed Pharmaceuticals' stock. Their forecasts range from $14.00 to $32.00. On average, they expect Galmed Pharmaceuticals' share price to reach $22.25 in the next twelve months. View Analyst Ratings for Galmed Pharmaceuticals.

Some companies that are related to Galmed Pharmaceuticals include Evolus (EOLS), Paratek Pharmaceuticals (PRTK), Corbus Pharmaceuticals (CRBP), Strongbridge Biopharma (SBBP), Unum Therapeutics (UMRX), Bellicum Pharmaceuticals (BLCM), Catalyst Pharmaceuticals (CPRX), Athersys (ATHX), Catalyst Biosciences (CBIO), Arbutus Biopharma (ABUS), Corium International (CORI), Corvus Pharmaceuticals (CRVS), Seres Therapeutics (MCRB), Durect (DRRX) and BioSpecifics Technologies (BSTC).

Media headlines about GLMD stock have been trending somewhat positive recently, according to Accern Sentiment Analysis. The research group identifies positive and negative press coverage by reviewing more than 20 million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Galmed Pharmaceuticals earned a media sentiment score of 0.23 on Accern's scale. They also gave media coverage about the biopharmaceutical company an impact score of 46.64 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company's share price in the next few days.

Galmed Pharmaceuticals' stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Park West Asset Management LLC (2.36%), UBS Group AG (0.26%) and A.R.T. Advisors LLC (0.12%). View Institutional Ownership Trends for Galmed Pharmaceuticals.

GLMD stock was purchased by a variety of institutional investors in the last quarter, including Park West Asset Management LLC, UBS Group AG and A.R.T. Advisors LLC. View Insider Buying and Selling for Galmed Pharmaceuticals.

Shares of GLMD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of GLMD stock can currently be purchased for approximately $6.17.

Galmed Pharmaceuticals has a market capitalization of $95.23 million and generates $1.09 million in revenue each year. The biopharmaceutical company earns $-12,290,000.00 in net income (profit) each year or ($0.98) on an earnings per share basis. Galmed Pharmaceuticals employs 16 workers across the globe.

Galmed Pharmaceuticals' mailing address is 16 ZE`EV TIOMKIN STREET, TEL AVIV L3, 6578317. The biopharmaceutical company can be reached via phone at 972-3693-8448.